Dong-Kun Yang, Ju-Yeon Lee, Minuk Kim, Hye Jeong Lee, Gyu-Nam Park, Yun Sang Cho
{"title":"ERAGS-GFP犬口服狂犬病疫苗的安全性和免疫原性评价。","authors":"Dong-Kun Yang, Ju-Yeon Lee, Minuk Kim, Hye Jeong Lee, Gyu-Nam Park, Yun Sang Cho","doi":"10.7774/cevr.2025.14.e29","DOIUrl":null,"url":null,"abstract":"<p><p>Rabies is a fatal zoonotic disease primarily transmitted through dog bites, making oral rabies vaccines critical for disease control. This study evaluated the immunogenicity of the ERAGS-GFP oral rabies vaccine strain in dogs. To optimize viral production, we examined cell density, multiplicity of infection (MOI), and freeze-thaw cycles. Safety was assessed via clinical monitoring, body temperature, and weight changes. Immunogenicity was evaluated using rabies virus neutralizing antibody (VNA) titers. Vero cells at MOI 2 with 3 freeze-thaw cycles yielded the highest viral titers. Vaccinated dogs showed no clinical symptoms and developed sustained protective VNA titers, demonstrating ERAGS-GFP's efficacy in rabies control.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"14 3","pages":"289-293"},"PeriodicalIF":1.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303705/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the safety and immunogenicity of the ERAGS-GFP oral rabies vaccine in dogs.\",\"authors\":\"Dong-Kun Yang, Ju-Yeon Lee, Minuk Kim, Hye Jeong Lee, Gyu-Nam Park, Yun Sang Cho\",\"doi\":\"10.7774/cevr.2025.14.e29\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Rabies is a fatal zoonotic disease primarily transmitted through dog bites, making oral rabies vaccines critical for disease control. This study evaluated the immunogenicity of the ERAGS-GFP oral rabies vaccine strain in dogs. To optimize viral production, we examined cell density, multiplicity of infection (MOI), and freeze-thaw cycles. Safety was assessed via clinical monitoring, body temperature, and weight changes. Immunogenicity was evaluated using rabies virus neutralizing antibody (VNA) titers. Vero cells at MOI 2 with 3 freeze-thaw cycles yielded the highest viral titers. Vaccinated dogs showed no clinical symptoms and developed sustained protective VNA titers, demonstrating ERAGS-GFP's efficacy in rabies control.</p>\",\"PeriodicalId\":51768,\"journal\":{\"name\":\"Clinical and Experimental Vaccine Research\",\"volume\":\"14 3\",\"pages\":\"289-293\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303705/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Vaccine Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7774/cevr.2025.14.e29\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2025.14.e29","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/19 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Evaluation of the safety and immunogenicity of the ERAGS-GFP oral rabies vaccine in dogs.
Rabies is a fatal zoonotic disease primarily transmitted through dog bites, making oral rabies vaccines critical for disease control. This study evaluated the immunogenicity of the ERAGS-GFP oral rabies vaccine strain in dogs. To optimize viral production, we examined cell density, multiplicity of infection (MOI), and freeze-thaw cycles. Safety was assessed via clinical monitoring, body temperature, and weight changes. Immunogenicity was evaluated using rabies virus neutralizing antibody (VNA) titers. Vero cells at MOI 2 with 3 freeze-thaw cycles yielded the highest viral titers. Vaccinated dogs showed no clinical symptoms and developed sustained protective VNA titers, demonstrating ERAGS-GFP's efficacy in rabies control.
期刊介绍：
Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
